Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Molecular aberrations and epigenetic dysregulation in NK-LGL leukemia

Marco Herling • 12 Jun 2022
EHA 2022
Leukemia Rare Diseases

Marco Herling, MD, University of Leipzig, Leipzig, Germany, discusses the pathogenesis of chronic natural killer large granular lymphocyte (NK-LGL) leukemia, commenting on the molecular landscape of this disease. Dr Herling explains that this disease is characterized by constitutive JAK/STAT signaling, with a large proportion of patients carrying mutations in TET2 or STAT3, thereby suggesting this pathway as a potential therapeutic target. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Marco Herling

Unmet needs in BPDCN: CNS involvement & the importance of intrathecal chemotherapy prophylaxis
1:00
Unmet needs in BPDCN: CNS involvement & the importance of intrathecal chemotherapy prophylaxis
Marco Herling • 25 Apr 2023
Improvements in the awareness and diagnosis of BPDCN
1:41
Improvements in the awareness and diagnosis of BPDCN
Marco Herling • 25 Apr 2023
Managing patients with transplant-ineligible BDPCN with tagraxofusp
1:15
Managing patients with transplant-ineligible BDPCN with tagraxofusp
Marco Herling • 25 Apr 2023
The challenge of relapse in transplant-eligible & transplant-ineligible patients with BDPCN
1:23
The challenge of relapse in transplant-eligible & transplant-ineligible patients with BDPCN
Marco Herling • 25 Apr 2023

Related Videos

Can treatment-free remission become a reality in polycythemia vera?
1:34
Can treatment-free remission become a reality in polycythemia vera?
Ruben Mesa • 2 Oct 2026
Beyond genomics: soluble proteomics for risk stratification and therapeutic targeting in AML
13:20
Beyond genomics: soluble proteomics for risk stratification and therapeutic targeting in AML
Hussein Abbas • 20 Sep 2026
Diphtheria toxin and tuspetinib: emerging therapies for TP53-mutated AML
11:44
Diphtheria toxin and tuspetinib: emerging therapies for TP53-mutated AML
Gabriel Mannis • 20 Sep 2026
AlloSCT in TP53-mutated AML: from patient selection to post-transplant care
13:26
AlloSCT in TP53-mutated AML: from patient selection to post-transplant care
Pramila Krishnamurthy • 20 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals